使用ACNU、长春新碱和尼卡地平进行化疗放疗并联合高剂量照射对恶性星形细胞瘤的疗效

Effect of chemoradiotherapy using ACNU, vincristine, and nicardipine with high-dose irradiation on malignant astrocytomas.

作者信息

Genka S, Shitara N, Nakamura H, Takakura K

机构信息

Department of Neurosurgery, University of Tokyo Hospital, Japan.

出版信息

Neurol Med Chir (Tokyo). 1993 May;33(5):295-9. doi: 10.2176/nmc.33.295.

DOI:10.2176/nmc.33.295

PMID:7687035

Abstract

Fifty-two patients with malignant astrocytoma were treated with cellular synchronization radiation therapy at the University of Tokyo Hospital between 1977 and 1989. Twenty-five patients (Group 1) received 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3- nitrosourea hydrochloride (ACNU), vincristine, and 60 Gy of irradiation, and 27 patients (Group 2) ACNU, vincristine, the Ca-channel blocker nicardipine, and 72 Gy of irradiation. Median survival times for Groups 1 and 2 were 15 and 30 months, respectively. Although there was no significant difference, Group 2 achieved longer survival with 1-, 2-, and 3-year survival rates of 85.2, 65.8, and 46.9% compared to rates of 66.7, 40.0, and 26.7%, respectively, for Group 1.

摘要

1977年至1989年间，东京大学医院对52例恶性星形细胞瘤患者进行了细胞同步放射治疗。25例患者（第1组）接受了盐酸1-(4-氨基-2-甲基-5-嘧啶基)甲基-3-(2-氯乙基)-3-亚硝基脲（ACNU）、长春新碱和60 Gy的照射，27例患者（第2组）接受了ACNU、长春新碱、钙通道阻滞剂尼卡地平以及72 Gy的照射。第1组和第2组的中位生存时间分别为15个月和30个月。虽然没有显著差异，但第2组的生存期更长，其1年、2年和3年生存率分别为85.2%、65.8%和46.9%，而第1组分别为66.7%、40.0%和26.7%。